Overview

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
Phase:
Phase 3
Details
Lead Sponsor:
University of Birmingham
Collaborator:
AstraZeneca
Treatments:
Cisplatin
Durvalumab